<DOC>
	<DOCNO>NCT00121212</DOCNO>
	<brief_summary>RATIONALE : Diagnostic procedure , positron emission tomography use carbon-11 acetate , may help find metastases prostate cancer may help predict whether prostate cancer come back treatment . PURPOSE : This clinical trial study well positron emission tomography use carbon-11 acetate work find metastasis predict recurrence patient prostate cancer risk recurrence treatment .</brief_summary>
	<brief_title>Positron Emission Tomography Prostate Cancer</brief_title>
	<detailed_description>The overall goal project determination role PET patient newly diagnose medium- high-risk prostate cancer standard clinical imaging workup negative . Thus , incremental value PET determine important group .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Inclusion Criteria Newly diagnose prostate cancer Has complete conventional staging examination , include biopsy Gleason score , CT scan abdomen pelvis , wholebody bone scintigraphy AND conventional stag examination negative Candidate curative radical prostatectomy OR curative radiotherapy OR stag lymphadenectomy prior surgery Deemed medium high risk recurrence initial curative treatment , define 1 follow criterion : Gleason score 7 AND prostatespecific antigen ( PSA ) 1020 ng/mL Gleason score ≥ 8 AND PSA &lt; 10 ng/mL Gleason score ≥ 8 AND PSA &gt; 10 ng/mL Any Gleason score AND PSA &gt; 20 ng/mL Exclusion Therapy : Not candidate treatment surgery radiation therapy curative intent Inability give inform consent Patients invasive malignancy , exception nonmelanoma skin cancer , ( ) evidence cancer present within last 5 year</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
</DOC>